ID   TOPK_HUMAN              Reviewed;         322 AA.
AC   Q96KB5; B4DX68; D3DST2; Q9NPD9; Q9NYL7; Q9NZK6;
DT   01-FEB-2005, integrated into UniProtKB/Swiss-Prot.
DT   06-DEC-2005, sequence version 3.
DT   12-OCT-2022, entry version 181.
DE   RecName: Full=Lymphokine-activated killer T-cell-originated protein kinase;
DE            EC=2.7.12.2;
DE   AltName: Full=Cancer/testis antigen 84;
DE            Short=CT84;
DE   AltName: Full=MAPKK-like protein kinase;
DE   AltName: Full=Nori-3;
DE   AltName: Full=PDZ-binding kinase;
DE   AltName: Full=Spermatogenesis-related protein kinase;
DE            Short=SPK;
DE   AltName: Full=T-LAK cell-originated protein kinase;
GN   Name=PBK; Synonyms=TOPK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, PHOSPHORYLATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Lymphoid tissue;
RX   PubMed=10781613; DOI=10.1074/jbc.m909629199;
RA   Abe Y., Matsumoto S., Kito K., Ueda N.;
RT   "Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-
RT   activated killer T-cell-originated protein kinase, specifically expressed
RT   in the testis and activated lymphoid cells.";
RL   J. Biol. Chem. 275:21525-21531(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PHOSPHORYLATION, MUTAGENESIS OF
RP   64-LEU-LEU-65; THR-320 AND VAL-322, INTERACTION WITH DLG1, AND VARIANT
RP   SER-107.
RX   PubMed=10779557; DOI=10.1073/pnas.090102397;
RA   Gaudet S., Branton D., Lue R.A.;
RT   "Characterization of PDZ-binding kinase, a mitotic kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:5167-5172(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT
RP   SER-107.
RC   TISSUE=Fetal brain;
RX   PubMed=11378444; DOI=10.1016/s1357-2725(01)00005-x;
RA   Zhao S., Dai J., Zhao W., Xia F., Zhou Z., Wang W., Gu S., Ying K., Xie Y.,
RA   Mao Y.;
RT   "PDZ-binding kinase participates in spermatogenesis.";
RL   Int. J. Biochem. Cell Biol. 33:631-636(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   SER-107.
RC   TISSUE=Embryo, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, INTERACTION WITH TP53, AND MUTAGENESIS OF THR-9.
RX   PubMed=17482142; DOI=10.1016/j.bbrc.2007.04.125;
RA   Nandi A.K., Ford T., Fleksher D., Neuman B., Rapoport A.P.;
RT   "Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase,
RT   involves protein-protein interaction with tumor suppressor p53.";
RL   Biochem. Biophys. Res. Commun. 358:181-188(2007).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells
RT   and high confident phosphopeptide identification by cross-validation of
RT   MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-24; SER-32 AND SER-59, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT THR-9; SER-32 AND SER-59, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-9 AND SER-59, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-169, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [17]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-107 AND LEU-241.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Phosphorylates MAP kinase p38. Seems to be active only in
CC       mitosis. May also play a role in the activation of lymphoid cells. When
CC       phosphorylated, forms a complex with TP53, leading to TP53
CC       destabilization and attenuation of G2/M checkpoint during doxorubicin-
CC       induced DNA damage. {ECO:0000269|PubMed:10781613,
CC       ECO:0000269|PubMed:17482142}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.12.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation. {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with DLG1 and TP53. {ECO:0000269|PubMed:10779557,
CC       ECO:0000269|PubMed:17482142}.
CC   -!- INTERACTION:
CC       Q96KB5; P10398: ARAF; NbExp=3; IntAct=EBI-536853, EBI-365961;
CC       Q96KB5; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-536853, EBI-742054;
CC       Q96KB5; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-536853, EBI-348259;
CC       Q96KB5; P04637: TP53; NbExp=7; IntAct=EBI-536853, EBI-366083;
CC       Q96KB5; Q8TF50: ZNF526; NbExp=3; IntAct=EBI-536853, EBI-11035148;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96KB5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96KB5-2; Sequence=VSP_055269;
CC   -!- TISSUE SPECIFICITY: Expressed in the testis and placenta. In the
CC       testis, restrictedly expressed in outer cell layer of seminiferous
CC       tubules. {ECO:0000269|PubMed:10781613, ECO:0000269|PubMed:11378444}.
CC   -!- PTM: Phosphorylated; in a cell-cycle dependent manner at mitosis.
CC       {ECO:0000269|PubMed:10779557, ECO:0000269|PubMed:10781613}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB027249; BAA99576.1; -; mRNA.
DR   EMBL; AB027250; BAA99577.1; -; mRNA.
DR   EMBL; AF189722; AAF69107.1; -; mRNA.
DR   EMBL; AF237709; AAF71521.1; -; mRNA.
DR   EMBL; AK027291; BAB55019.1; -; mRNA.
DR   EMBL; AK301836; BAG63280.1; -; mRNA.
DR   EMBL; AC104997; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471080; EAW63536.1; -; Genomic_DNA.
DR   EMBL; CH471080; EAW63537.1; -; Genomic_DNA.
DR   EMBL; BC015191; AAH15191.1; -; mRNA.
DR   CCDS; CCDS6063.1; -. [Q96KB5-1]
DR   CCDS; CCDS64858.1; -. [Q96KB5-2]
DR   RefSeq; NP_001265874.1; NM_001278945.1. [Q96KB5-2]
DR   RefSeq; NP_060962.2; NM_018492.3. [Q96KB5-1]
DR   RefSeq; XP_006716431.1; XM_006716368.2.
DR   PDB; 5J0A; X-ray; 2.74 A; A=23-320, B=19-319.
DR   PDBsum; 5J0A; -.
DR   AlphaFoldDB; Q96KB5; -.
DR   SMR; Q96KB5; -.
DR   BioGRID; 120971; 89.
DR   IntAct; Q96KB5; 29.
DR   MINT; Q96KB5; -.
DR   STRING; 9606.ENSP00000428489; -.
DR   BindingDB; Q96KB5; -.
DR   ChEMBL; CHEMBL4896; -.
DR   GuidetoPHARMACOLOGY; 2140; -.
DR   GlyGen; Q96KB5; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q96KB5; -.
DR   PhosphoSitePlus; Q96KB5; -.
DR   BioMuta; PBK; -.
DR   DMDM; 83305809; -.
DR   EPD; Q96KB5; -.
DR   jPOST; Q96KB5; -.
DR   MassIVE; Q96KB5; -.
DR   MaxQB; Q96KB5; -.
DR   PaxDb; Q96KB5; -.
DR   PeptideAtlas; Q96KB5; -.
DR   PRIDE; Q96KB5; -.
DR   ProteomicsDB; 5416; -.
DR   ProteomicsDB; 77056; -. [Q96KB5-1]
DR   ABCD; Q96KB5; 2 sequenced antibodies.
DR   Antibodypedia; 1595; 584 antibodies from 36 providers.
DR   DNASU; 55872; -.
DR   Ensembl; ENST00000301905.9; ENSP00000301905.4; ENSG00000168078.10. [Q96KB5-1]
DR   Ensembl; ENST00000522944.5; ENSP00000428489.1; ENSG00000168078.10. [Q96KB5-2]
DR   GeneID; 55872; -.
DR   KEGG; hsa:55872; -.
DR   MANE-Select; ENST00000301905.9; ENSP00000301905.4; NM_018492.4; NP_060962.2.
DR   UCSC; uc011lap.4; human. [Q96KB5-1]
DR   CTD; 55872; -.
DR   DisGeNET; 55872; -.
DR   GeneCards; PBK; -.
DR   HGNC; HGNC:18282; PBK.
DR   HPA; ENSG00000168078; Group enriched (lymphoid tissue, testis).
DR   MIM; 611210; gene.
DR   neXtProt; NX_Q96KB5; -.
DR   OpenTargets; ENSG00000168078; -.
DR   PharmGKB; PA134925802; -.
DR   VEuPathDB; HostDB:ENSG00000168078; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   GeneTree; ENSGT00720000108839; -.
DR   HOGENOM; CLU_044128_1_0_1; -.
DR   InParanoid; Q96KB5; -.
DR   OMA; TFKMIMD; -.
DR   OrthoDB; 1030296at2759; -.
DR   PhylomeDB; Q96KB5; -.
DR   TreeFam; TF329763; -.
DR   PathwayCommons; Q96KB5; -.
DR   SignaLink; Q96KB5; -.
DR   SIGNOR; Q96KB5; -.
DR   BioGRID-ORCS; 55872; 9 hits in 1109 CRISPR screens.
DR   ChiTaRS; PBK; human.
DR   GeneWiki; PBK_(gene); -.
DR   GenomeRNAi; 55872; -.
DR   Pharos; Q96KB5; Tchem.
DR   PRO; PR:Q96KB5; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q96KB5; protein.
DR   Bgee; ENSG00000168078; Expressed in ventricular zone and 127 other tissues.
DR   ExpressionAtlas; Q96KB5; baseline and differential.
DR   Genevisible; Q96KB5; HS.
DR   GO; GO:0005634; C:nucleus; IDA:CACAO.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004706; F:JUN kinase kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:RHEA.
DR   GO; GO:0034644; P:cellular response to UV; IEA:Ensembl.
DR   GO; GO:0000278; P:mitotic cell cycle; NAS:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0032435; P:negative regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0032873; P:negative regulation of stress-activated MAPK cascade; IEA:Ensembl.
DR   GO; GO:0038066; P:p38MAPK cascade; IBA:GO_Central.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:1904291; P:positive regulation of mitotic DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   CDD; cd14001; PKc_TOPK; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR041989; PKc_TOPK.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Isopeptide bond; Kinase; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Ubl conjugation.
FT   CHAIN           1..322
FT                   /note="Lymphokine-activated killer T-cell-originated
FT                   protein kinase"
FT                   /id="PRO_0000086763"
FT   DOMAIN          32..322
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          320..322
FT                   /note="PDZ-interaction"
FT   ACT_SITE        167
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         38..46
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         64
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:22223895"
FT   MOD_RES         9
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         24
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         32
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         59
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   CROSSLNK        169
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         198
FT                   /note="T -> TAPAFITILLVS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055269"
FT   VARIANT         107
FT                   /note="N -> S (in dbSNP:rs3779620)"
FT                   /evidence="ECO:0000269|PubMed:10779557,
FT                   ECO:0000269|PubMed:11378444, ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_021162"
FT   VARIANT         220
FT                   /note="E -> D (in dbSNP:rs17057901)"
FT                   /id="VAR_051676"
FT   VARIANT         241
FT                   /note="M -> L (in dbSNP:rs36086402)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041234"
FT   MUTAGEN         9
FT                   /note="T->E: TP53-binding."
FT                   /evidence="ECO:0000269|PubMed:17482142"
FT   MUTAGEN         64..65
FT                   /note="KK->AA: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:10779557"
FT   MUTAGEN         320
FT                   /note="T->A: Decrease in the binding to DLG1."
FT                   /evidence="ECO:0000269|PubMed:10779557"
FT   MUTAGEN         322
FT                   /note="V->A: Decrease in the binding to DLG1."
FT                   /evidence="ECO:0000269|PubMed:10779557"
FT   CONFLICT        34
FT                   /note="F -> I (in Ref. 3; AAF71521)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        169
FT                   /note="K -> E (in Ref. 4; BAB55019)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        254
FT                   /note="D -> N (in Ref. 4; BAB55019)"
FT                   /evidence="ECO:0000305"
FT   STRAND          26..29
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           34..37
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   STRAND          44..48
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           54..57
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           60..65
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           69..71
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           73..77
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   STRAND          78..82
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           83..91
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   STRAND          100..105
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   STRAND          108..115
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   STRAND          120..122
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           123..131
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   TURN            132..134
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           140..159
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           170..172
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   STRAND          173..176
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   TURN            177..180
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   STRAND          181..184
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   STRAND          189..192
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           210..212
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           215..217
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   STRAND          219..221
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           227..242
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   STRAND          250..252
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   TURN            254..256
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           263..265
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           268..274
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   TURN            283..285
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           291..300
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           305..307
FT                   /evidence="ECO:0007829|PDB:5J0A"
FT   HELIX           311..319
FT                   /evidence="ECO:0007829|PDB:5J0A"
SQ   SEQUENCE   322 AA;  36085 MW;  6BF55789BC204ABE CRC64;
     MEGISNFKTP SKLSEKKKSV LCSTPTINIP ASPFMQKLGF GTGVNVYLMK RSPRGLSHSP
     WAVKKINPIC NDHYRSVYQK RLMDEAKILK SLHHPNIVGY RAFTEANDGS LCLAMEYGGE
     KSLNDLIEER YKASQDPFPA AIILKVALNM ARGLKYLHQE KKLLHGDIKS SNVVIKGDFE
     TIKICDVGVS LPLDENMTVT DPEACYIGTE PWKPKEAVEE NGVITDKADI FAFGLTLWEM
     MTLSIPHINL SNDDDDEDKT FDESDFDDEA YYAALGTRPP INMEELDESY QKVIELFSVC
     TNEDPKDRPS AAHIVEALET DV
//
